Intocell
Daejeon
About Intocell
Intocell is a biotechnology company that develops an antibody-drug conjugate platform for the R&D and commercialization of biopharmaceuticals. Intocell creates protein-drug complexes, antibody-drug complexes, and other complexes with their own linkers and drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $32.1M
- Funding stage: IPO
- Last round: Series C (Jan 2021)
- Ticker: kosdaq:287840
- Website: intocell.com
Industries & Categories
Biotechnology, Information Technology, Medical
Social Profiles
Canonical: https://fsome.com/organization/intocell-12828 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.